诺和诺德司美格鲁肽在去年同“药王”失之交臂后,终于在今年第一季度成功问鼎。 司美格鲁肽的成功在业内掀起了全球减重赛道的研发热潮,众多MNC开始将管线聚焦于此。而位于产业链上游的医药外包(CXO)公司也迎来了新的增量。 “药王”易主 近年来,司美格鲁肽在市场上的火爆,让业内对其早就寄予厚望。 2024年,就有观点认为,司美格鲁肽将撼动K药全球“药王”的地位。但最终财报信息显示,全球“药王”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.